SCHEMBL10248903

SCHEMBL10248903

Cc1cnc2c(c1)nc(-c1ccncc1F)n2C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PDE10A Q9Y233 1/20 0.37
AKT1 P31749 2/20 0.36
AKT2 P31751 2/20 0.36
LATS1 O95835 4/20 0.36
CYP11B2 P19099 3/20 0.36
LATS2 Q9NRM7 2/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
CYP11B1 P15538 2/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
RPS6KA3 P51812 1/20 0.35
GABRA1 P14867 1/20 0.34
NUDT1 P36639 2/20 0.34
ATM Q13315 1/20 0.34
KCNH2 Q12809 1/20 0.34
AOC3 Q16853 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4403186 0.86 PDE10A (0.40) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL116863 0.85 POLB (0.43) POLBSMN1; SMN2PDE10ALATS1CYP11B2
SCHEMBL4399161 0.84 POLB (0.38) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249307 0.84 PDE10A (0.38) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10248996 0.84 PDE10A (0.40) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL15426465 0.83 HSD11B1 (0.41) PDE10AAKT1AKT2CYP11B2CYP11B1
SCHEMBL10249367 0.82 MAPT (0.40) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249224 0.82 PDE10A (0.40) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249007 0.82 POLB (0.36) POLBSMN1; SMN2PDE10AAKT1AKT2
SCHEMBL10249083 0.82 POLB (0.50) POLBSMN1; SMN2PDE10AAKT1AKT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 POLB 4724/4885SMN1; SMN2 1524/4885PDE10A 4112/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 POLB 4724/4885SMN1; SMN2 1524/4885PDE10A 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.